BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12227070)

  • 1. [Non-specific changes in the complement system in neoplastic processes].
    Tiagotin IuV; Rybakova LP; Golota GZ; Ishchenko AM
    Vopr Onkol; 2002; 48(2):206-10. PubMed ID: 12227070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Complement. Evaluation of some complement fractions in patients affected by neoplasia undergoing chemotherapy (author's transl)].
    Ignesti C; Lenzi L; Salvadori D; Innocenti V; Baroncelli C; Casadei BM
    Quad Sclavo Diagn; 1981 Jun; 17(2):152-6. PubMed ID: 6943601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Levels of complement components in plasma of onco-hematologic patients with defective hemopoiesis].
    Rybakova LP; Tiagotin IV; Ganapiev AA; Moiseev SI; Ushakova EA; Abdulkadyrov KM; Ishchenko AM
    Vopr Onkol; 1996; 42(2):63-7. PubMed ID: 8815636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulins and complement components in patients with lung cancer.
    Oner F; Savaş I; Numanoğlu N
    Tuberk Toraks; 2004; 52(1):19-23. PubMed ID: 15143368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of aging on complement activity (CH50) and complement protein levels.
    Nagaki K; Hiramatsu S; Inai S; Sasaki A
    J Clin Lab Immunol; 1980 Jan; 3(1):45-50. PubMed ID: 7381926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total hemolytic complement (CH50) and its fractions C3 and C4 in the sera of patients with localized juvenile periodontitis.
    Anil S; Beena VT; Remani P; Mysore J; Vijayakumar T
    Ann Dent; 1993; 52(1):18-20. PubMed ID: 8323245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes of serum complement and of circulating immune complexes in patients with multiple sclerosis.
    Cojocaru M; Serbănescu A; Cojocaru IM
    Rom J Intern Med; 1993; 31(2):131-7. PubMed ID: 8268831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correction of complement system failure in patients with chronic prostatitis].
    Teodorovich OV; Shatokhin MN; Mykolaenko TV; Konoplia AI; Krasnov AV; Mavrin MIu; Meshanin NV
    Urologiia; 2011; (4):29-32. PubMed ID: 22066238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which complement assays and typings are necessary for the diagnosis of complement deficiency in patients with lupus erythematosus? A study of 25 patients.
    Boeckler P; Meyer A; Uring-Lambert B; Goetz J; Cribier B; Hauptmann G; Lipsker D
    Clin Immunol; 2006 Nov; 121(2):198-202. PubMed ID: 16987709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The difference between serum and plasma complement activity in primary renal disease.
    Akagaki Y; Fujiwara Y; Nakanishi I; Orita Y; Ando A; Abe H; Kitamura H; Nagaki K; Inai S
    Clin Nephrol; 1980 Aug; 14(2):75-80. PubMed ID: 7408259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total hemolytic complement (CH50) and its fractions (C3 and C4) in the sera of patients with carcinoma of the oral cavity, uterine cervix, and breast.
    Vijayakumar T; Ankathil R; Remani P; Beevi VM; Vijayan KK; Panicker CK
    J Clin Immunol; 1987 Jul; 7(4):300-3. PubMed ID: 3611297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement regulation in murine and human hypercholesterolemia and role in the control of macrophage and smooth muscle cell proliferation.
    Verdeguer F; Castro C; Kubicek M; Pla D; Vila-Caballer M; Vinué A; Civeira F; Pocoví M; Calvete JJ; Andrés V
    Cardiovasc Res; 2007 Nov; 76(2):340-50. PubMed ID: 17673191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement and its fractions (C3-C4) pattern in subjects with neoplasia.
    Mangano A; Messina L; Birgillito S; Stivala F; Bernardini A
    J Immunopharmacol; 1984; 6(3):147-62. PubMed ID: 6491311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classical pathway complement activity in schizophrenia.
    Hakobyan S; Boyajyan A; Sim RB
    Neurosci Lett; 2005 Feb; 374(1):35-7. PubMed ID: 15631892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Autoantibodies to steroid-producing ovarian cells in cancer patients].
    Bershteĭn LM; Poroshina TE; Vasil'ev DA; Orlova AV
    Vopr Onkol; 2008; 54(5):602-5. PubMed ID: 19069474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of complement in sera from inactive SLE patients, although decreased, do not influence in vitro uptake of apoptotic cells.
    Grevink ME; Horst G; Limburg PC; Kallenberg CG; Bijl M
    J Autoimmun; 2005 Jun; 24(4):329-36. PubMed ID: 15927794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change of complement system predicts the outcome of patients with severe thermal injury.
    Kang HJ; Kim JH; Lee EH; Lee YK; Hur M; Lee KM
    J Burn Care Rehabil; 2003; 24(3):148-53. PubMed ID: 12792234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring the level of complement components during autologous blood stem cell transplantation in patients with malignant lymphomas.
    Banyai A; Varga L; Barta A; Gopcsa L; Paloczi K
    Cancer Immunol Immunother; 2004 Sep; 53(9):835-9. PubMed ID: 15052374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer.
    Yousef GM; Polymeris ME; Grass L; Soosaipillai A; Chan PC; Scorilas A; Borgoño C; Harbeck N; Schmalfeldt B; Dorn J; Schmitt M; Diamandis EP
    Cancer Res; 2003 Jul; 63(14):3958-65. PubMed ID: 12873991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunofluorescence studies in stomach and breast carcinomas and benign breast diseases].
    Kasper M
    Acta Histochem; 1984; 75(1):37-45. PubMed ID: 6438999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.